These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28648553)

  • 41. Brain derived neurotrophic factor (BDNF) levels in depressed women treated with open-label escitalopram.
    Ladea M; Bran M
    Psychiatr Danub; 2013 Jun; 25(2):128-32. PubMed ID: 23793276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
    Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
    J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Salardini E; Zeinoddini A; Mohammadinejad P; Khodaie-Ardakani MR; Zahraei N; Zeinoddini A; Akhondzadeh S
    J Psychiatr Res; 2016 Apr; 75():24-30. PubMed ID: 26800392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression.
    Fang Y; Qiu Q; Zhang S; Sun L; Li G; Xiao S; Li X
    J Affect Disord; 2018 Feb; 227():745-751. PubMed ID: 29689690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
    Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
    Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
    Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy.
    Nehama Y; Rabinowitz I; Baruch Y; Mandel A; Lurie I; Barak Y
    Int Clin Psychopharmacol; 2014 Mar; 29(2):106-10. PubMed ID: 24172161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyroid autoimmunity and treatment response to escitalopram in major depression.
    Eller T; Metsküla K; Talja I; Maron E; Uibo R; Vasar V
    Nord J Psychiatry; 2010 Aug; 64(4):253-7. PubMed ID: 20088751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial.
    Scantamburlo G; Hansenne M; Geenen V; Legros JJ; Ansseau M
    Eur Psychiatry; 2015 Jan; 30(1):65-8. PubMed ID: 25282363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder.
    Zhou J; Zhou J; Sun Z; Feng L; Feng Y; Xiao L; Chen X; Yang J
    J Affect Disord; 2022 Jun; 306():32-38. PubMed ID: 35271871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
    Tsuchimine S; Ochi S; Tajiri M; Suzuki Y; Sugawara N; Inoue Y; Yasui-Furukori N
    Ther Drug Monit; 2018 Jun; 40(3):356-361. PubMed ID: 29570504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
    Erabi H; Okada G; Shibasaki C; Setoyama D; Kang D; Takamura M; Yoshino A; Fuchikami M; Kurata A; Kato TA; Yamawaki S; Okamoto Y
    Sci Rep; 2020 Oct; 10(1):16822. PubMed ID: 33033336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression.
    Kim YG; Chang HS; Won ES; Ham BJ; Lee MS
    Neuropsychobiology; 2014; 69(4):210-9. PubMed ID: 24903772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
    Jiang H; Chen S; Lu N; Yue Y; Yin Y; Zhang Y; Jiang W; Liang J; Yuan Y
    World J Biol Psychiatry; 2017 Dec; 18(8):586-591. PubMed ID: 28635540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
    Yang J; Zhou J; Zhou J; Wang H; Sun Z; Zhu X; He Y; Wong AHC; Liu F; Wang G
    J Psychiatr Res; 2022 Feb; 146():172-178. PubMed ID: 34995992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
    Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression.
    Brunoni AR; Padberg F; Vieira ELM; Teixeira AL; Carvalho AF; Lotufo PA; Gattaz WF; Benseñor IM
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():211-217. PubMed ID: 29894705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.